Benzinga’s Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)

Tiffany & Co. (NYSE: TIF) rose 6.26% to $44.45 in the pre-market session after TIF announced that for the fourth quarter, it expects sales to increase and also provided outlook for fiscal 2009. For financial year 2009, TIF expects EPS to be in between $1.88 - $1.98 while analysts are expecting TIF to report EPS of $1.77 for financial year 2009. So far in 2009, TIF climbed up over 75%.

RF Micro Devices, Inc. (NASDAQ: RFMD) climbed 1.36% or $0.06 to $4.47 in the pre-market session. Yesterday, RFMD announced that RFMD’s executives are scheduled to present at the Credit Suisse Annual Technology Conference in Scottsdale, on December 01, 2009. The 52 week trading range for RFMD is $0.70 - $5.85.

Aixtron AG (ADR) (NASDAQ: AIXG) jumped 3.16% to $35.63 in the pre-market session. The 52 week trading range for AIXG is $3.86 - $38.04. So far in 2009, AIXG gained over 400%. Yesterday, AIXG closed at $34.54.

Incyte Corporation (NASDAQ: INCY) moved up 15.28% to $8.90 in the pre-market trading after Incyte announced that it has entered into a collaboration and license agreement with Novartis AG (NYSE: NVS) for two of its investigational hematology-oncology therapies. As a result, Novartis will pay Incyte up to $1.1 billion for the deal, which involves the development of therapies that treat myelofibrosis and multiple cancers, are met.

Solarfun Power Holdings Co., Ltd. (ADR) (NASDAQ: SOLF) surged 4.43% to $6.60 after Solarfun Power Holdings announced that it has appointed Gareth Kung as the Chief Financial Officer (CFO). Yesterday, SOLF closed at $6.32.

Qiagen NV (NASDAQ: QGEN) climbed 2.43% to $21.88 in the pre-market trading hours. The 52 week trading range for QGEN is $14.32 - $23.58. Yesterday, QGEN closed at $21.36. So far in 2009, QGEN gained over 20%.

Cytori Therapeutics Inc. (USA) (NASDAQ: CYTX) increased 3.24% to $5.10 in the pre-market session. The 52 week trading range for CYTX is $1.42 - $5.14. So far in 2009, CYTX gained over 35%.

Sinovac Biotech Ltd. (NASDAQ: SVA) moved up 3.47% to $7.21 after Sinovac executed a joint venture to expand human-use vaccine development and manufacturing capabilities. So far in 2009, SVA declined by over 20%.